N-乙基-1-甲基-1H-苯并咪唑-5-胺 | 190843-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: N-乙基-1-甲基-1H-苯并咪唑-5-胺
• 英文名称: 5-(N-ethylamino)-1-methyl-1H-benzimidazole
• 英文别名: N-ethyl-1-methylbenzimidazol-5-amine
• CAS: 190843-75-5
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.233
• InChiKey: LWZBOEIPEHXCIG-UHFFFAOYSA-N

物化性质

• 沸点：
  349.9±34.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硫氰酸铵 、 2-氯烟酸 、 2-chloronicotinoyl chloride 、 N-乙基-1-甲基-1H-苯并咪唑-5-胺 、 2-chloronicotinoyl isothiocyanate 在 氯化亚砜 作用下， 以 ice-water 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 为溶剂， 生成 2-[N-ethyl-N-(1H-1-methylbenzimidazol-5-yl)amino]-4H-pyrido[3,2-e]-1,3-thiazin-4-one hydrochloride
  参考文献：
  名称：

  Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative

  摘要：

  基于抑制kainic酸神经毒性的神经保护剂和作为神经保护剂的化合物。一种kainic酸神经毒性抑制剂，包括以下通式(I)所代表的吡啶噻嗪衍生物或其药学上可接受的盐作为活性成分，以及以下通式(I)所代表的吡啶噻嗪衍生物或其药学上可接受的盐：##STR1## 公式中的符号具有以下各自的含义：环A：吡啶环；##STR2## R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5可以相同也可以不同，每个代表氢原子或较低的烷基、环烷基、烯烃基、芳基、羧基或较低的烷氧羰基基团，这些基团可能带有取代基，或者不存在，但需注意R.sup.2和R.sup.3可以共同形成含氮的杂环基团，该基团可能含有氮原子作为另一种杂原子，可能与苯环融合，并且可能具有较低的烷基基团作为取代基。

  公开号：

  US06133258A1

文献信息

• Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation
  申请人：Edlin Christopher

  公开号：US20070191426A1

  公开（公告）日：2007-08-16

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.

  化合物I式或其药学上可接受的盐是磷酸二酯酶IV型（PDE4）的抑制剂，可用于治疗炎症和/或过敏性疾病。
• KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0878196A1

  公开（公告）日：1998-11-18

  Neuron protective agents on the basis of the inhibition of neuronotoxicity of kainic acid and compounds useful as such agents. Pyridothiazine derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof and neuronotoxicity inhibitors containing as the active ingredient these compounds or pharmaceutically acceptable salts thereof, wherein A represents a pyridine ring; formula (II) represents formula (III) or formula (IV); and R1, R2, R3, R4 and R5 are the same or different and each represents hydrogen, optionally substituted lower alkyl, cycloalkyl, alkenyl, aryl, carboxy or lower alkoxycarbonyl or does not exist, or R2 and R3 together form a nitrogenous heterocycle optionally having a nitrogen atom as another heteroatom, being fused with a benzene ring, or being substituted by lower alkyl.

  以抑制凯宁酸神经毒性为基础的神经元保护剂以及可用作此类保护剂的化合物。通式(I)代表的吡啶噻嗪衍生物或其药学上可接受的盐，以及含有这些化合物或其药学上可接受的盐作为活性成分的神经元毒性抑制剂，其中 A 代表吡啶环；式(II)代表式(III)或式(IV)；R1、R2、R3、R4 和 R5 相同或不同，各自代表氢、任选取代的低级烷基、环烷基、烯基、芳基、羧基或低级烷氧基羰基或不存在，或 R2 和 R3 共同形成一个含氮杂环，任选具有一个氮原子作为另一个杂原子，与苯环融合，或被低级烷基取代。
• Antiviral drugs for treatment of arenavirus infection
  申请人：Hruby E. Dennis

  公开号：US20070254934A1

  公开（公告）日：2007-11-01

  Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
• ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION
  申请人：Hruby Dennis E.

  公开号：US20080300265A1

  公开（公告）日：2008-12-04

  Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).
• Anti-Viral Drugs for Treatment of Arenavirus Infection
  申请人：Hruby Dennis E.

  公开号：US20110172281A1

  公开（公告）日：2011-07-14

  Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).